Vesicular formulations

Abstract

Disclosed herein are vesicular formulations that include one or more phospholipids and one or more surfactants and in certain embodiments the use of such formulations for the delivery of fatty acids for the treatment of disorders such as, fatty acid metabolic disorders, including essential fatty acid deficiency; pain or inflammation or osteoarthritis, more specifically for the treatment of deep tissue pain; asthma, bronchospasm, atherothrombatic cardiovascular disorders, avenous thrombatic disorders, inflammatory dermatoses disorders (e.g., atopic eczema, dishydrotic hand eczema, plaque type psoriasis, seborrheic eczema, and acne vulgaris), and dysmenorrhea.

1 - 122 . (canceled) 
     
     
         123 . A vesicular formulation for use in the treatment of inflammatory dermatoses disorders, gout or fungal infection comprising one or more phospholipids and one or more surfactants, in the absence of a pharmaceutically active agent. 
     
     
         124 . A vesicular formulation as claimed in claim  1 , for use in the treatment of atopic eczema, dishydrotic hand eczema, plaque type psoriasis, seborrheic eczema, or acne vulgaris. 
     
     
         125 . A vesicular formulation of claim  1 , wherein the formulation is a cream, lotion, ointment, gel, solution, spray, lacquer or film forming solution. 
     
     
         126 . A vesicular formulation as claimed in claim  1 , wherein the ratio of phospholipid to surfactant is about 1:3 to about 30:1. 
     
     
         127 . A vesicular formulation, as claimed in claim  1 , wherein the formulation contains 2.0-10.0% by weight phospholipid. 
     
     
         128 . A vesicular formulation, as claimed in claim  1 , wherein the formulation contains 1.0-5.0% by weight surfactant. 
     
     
         129 . A vesicular formulation, as claimed in claim  1 , wherein the formulation contains 0.2% to about 0.5% by weight surfactant. 
     
     
         130 . A vesicular formulation, as claimed in claim  1 , wherein the phospholipid is phosphatidylcholine. 
     
     
         131 . A vesicular formulation, as claimed in claim  1 , wherein the surfactant is a nonionic surfactant selected from the group consisting of: polyoxyethylene sorbitans, polyhydroxyethylene stearates or polyhydroxethylene laurylethers. 
     
     
         132 . A vesicular formulation, as claimed in claim  1 , wherein the surfactant is polysorbate 80 (Tween 80).